Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mete Kalak"'
Autor:
Vefki Gürhan Kadıköylü, İbrahim Meteoğlu, Süleyman Demir, Hülya Aybek, Mete Kalak, Muharrem Balkaya, Çiğdem Yenisey, Zahit Bolaman
Publikováno v:
Turkish Journal of Hematology, Vol 27, Iss 02, Pp 62-69 (2010)
Objective: Amifostine (AMI) has been used for the prevention of doxorubicin-induced cardiotoxicity in several experimental and a few clinical studies. The aim of this study was to investigate the effects of AMI on lipid peroxidation, protective enzym
Externí odkaz:
https://doaj.org/article/6c175b3c3172440487f79127d34d341a
Autor:
Hülya Aybek, Vefki Gürhan Kadıköylü, Zahit Bolaman, Süleyman Demir, Mete Kalak, Muharrem Balkaya, Cigdem Yenisey, Ibrahim Meteoglu
Publikováno v:
Turkish Journal of Hematology, Vol 27, Iss 02, Pp 62-69 (2010)
Amifostine (AMI) has been used for the prevention of doxorubicin-induced cardiotoxicity in several experimental and a few clinical studies. The aim of this study was to investigate the effects of AMI on lipid peroxidation, protective enzymes, and mit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::299c8bbac281c4010c764afb78180941
https://pubmed.ncbi.nlm.nih.gov/27263446
https://pubmed.ncbi.nlm.nih.gov/27263446
Autor:
Mete Kalak, Süleyman Demir, Hülya Aybek, Cigdem Yenisey, Ibrahim Meteoglu, Muharrem Balkaya, Gurhan Kadikoylu, Mutlu Arat, Zahit Bolaman
Publikováno v:
Web of Science
Background: Mitoxantrone (MTX), an anthracenedione derivate, is used in the treatment of several malignancies. One of the most important adverse effects is dose-dependent cardiotoxicty. Myocardial adrenergic imbalance, oxygen free radicals, tumor nec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eb6de6a9f94e6ae2aa706e4997a301f
https://doi.org/10.1182/blood.v108.11.4364.4364
https://doi.org/10.1182/blood.v108.11.4364.4364